Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.

@article{Richards1993Endopeptidase2I,
  title={Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.},
  author={Arthur Mark Richards and Ian George Crozier and Teddy Kosoglou and M C Rallings and E A Espiner and M. G. Nicholls and Timothy G. Yandle and Hamid Ikram and Chris Frampton},
  journal={Hypertension},
  year={1993},
  volume={22 1},
  pages={119-26}
}
The detailed integrated renal, hormonal, and hemodynamic effects of acute (first dose) and established (4 days) inhibition of endopeptidase 24.11 by SCH 42495 (200 mg, every 12 hours) were documented in eight patients with essential hypertension in a double-blind, balanced random-order, crossover study. SCH 42495 suppressed plasma endopeptidase activity (> 90%, P < .001) for the duration of the dosing period. Initially, plasma atrial natriuretic factor levels increased markedly (+123%, P < .01… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Antihypertensive and hemodynamic effects of the neutral endopeptidase inhibitor prodrug SCH 42495

  • RW Watkins, P Chiu, +6 authors EJ. Sybertz
  • Am J Hypertens. 1991;4:32A. Abstract
  • 1991

Inhibition of endopeptidase 24.11 in essential hypertension: hemodynamic and hormonal effects

  • AM Richards, G Wittert, IG Crozier, EA Espiner, TG Yandle, H. Ikram
  • Circulation
  • 1991

Similar Papers

Loading similar papers…